We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Volatile Breath Compounds Associated with Laryngeal Carcinomas

By LabMedica International staff writers
Posted on 06 May 2014
Print article
Image: Exhaling into a tedlar bag for volatile organic compound analysis (Photo courtesy of the Information and Scientific News Service (SINC).
Image: Exhaling into a tedlar bag for volatile organic compound analysis (Photo courtesy of the Information and Scientific News Service (SINC).
Exhaled breath contains thousands of gaseous volatile organic compounds (VOCs) that may be used as noninvasive markers of head and neck epidermoid cancer.

The technique of solid phase microextraction (SPME) may be useful for the analysis of exhaled air and it is one of the methods used to concentrate volatile organic compounds emitted by different sources.

Scientists at the Rey Juan Carlos University (Madrid, Spain) and the Foundation Hospital (Alcorcón, Spain) compared the volatile substances exhaled by 11 people with cancer of larynx in various phases of the disease, with those of another 20 healthy people, half of whom were smokers. The participants exhaled breath into tedlar bags after fasting for at least eight hours so there was no leftover food or drink on their breath.

The samples were then analyzed with solid phase microextraction, gas chromatography and mass spectrometry equipment (Agilent [Varian inc.], Palo Alto, CA, USA) which enable very small amounts of a substance to be separated and identified. The concentrations are around or slightly above the equipment's detection limits, 40 ng/mL, which is equivalent to 40 ppb (parts per billion).

The investigators found that that the air exhaled by the more seriously ill patients, in a stage called T3, contains different concentrations of seven compounds compared with the levels of healthy people or even those with a less developed tumor (T1). Specifically, in the graphics of individuals with advanced cancer, the peaks that represent ethanol (C2H6O) and 2-butanone (C4H8O) are particularly significant. These two compounds therefore become potential markers of laryngeal carcinoma.

A total of 31 common VOCs in non-smokers have been determined, whereas smokers reach up to 45 VOCs, thus differentiating the two types of populations. The study also identified four markers in the exhaled breath that are typical of smokers, such as benzene and furfural. The four marker compounds that were found and related to cigarette smoking but absent in nonsmokers, and these were: cyclohexa-1,3,5-triene (benzene), fural-dehyde, 4-isobutyl-1-(1-hydroxyethyl)-benzene, and 2,3,5-trimethylhexane.

Rafael A.García, PhD, a professor of Chemical Engineering, and lead author of the study said, “At the moment it is still a preliminary study and a wider sample has to be obtained but it is a step in the right direction, an alternative with regard to identifying biomarkers, not only for this type of cancer but for other more prevalent and serious ones such as lung cancer, where early detection is key.” The study was published in the March 2014 issue of the journal Chromatographia.

Related Links:

Rey Juan Carlos University
Foundation Hospital
Agilent


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.